Literature DB >> 33623713

Calumenin contributes to epithelial-mesenchymal transition and predicts poor survival in glioma.

Ying Yang1, Jin Wang2, Shihai Xu2, Fei Shi2, Aijun Shan2.   

Abstract

BACKGROUND: Calumenin (CALU) has been reported to be associated with invasiveness and metastasis in some malignancies. However, in glioma, the role of CALU remains unclear.
METHODS: Clinical and transcriptome data of 998 glioma patients, including 301 from CGGA and 697 from TCGA dataset, were included. R language was used to perform statistical analyses.
RESULTS: CALU expression was significantly upregulated in more malignant gliomas, including higher grade, IDH wildtype, mesenchymal, and classical subtype. Gene Ontology analysis revealed that CALU-correlated genes were mainly enriched in cell/biological adhesion, response to wounding, and extracellular matrix/structure organization, all of which were strongly correlated with the epithelial-mesenchymal transition (EMT) phenotype. GSEA further validated the profound involvement of CALU in EMT. Subsequent GSVA suggested that CALU was particularly correlated with three EMT signaling pathways, including TGFβ, PI3K/AKT, and hypoxia pathway. Furthermore, CALU played synergistically with EMT key markers, including N-cadherin, vimentin, snail, slug, and TWIST1. Survival and Cox regression analysis showed that higher CALU predicted worse survival, and the prognostic value was independent of WHO grade and age.
CONCLUSIONS: CALU was correlated with more malignant phenotypes in glioma. Moreover, CALU seemed to serve as a pro-EMT molecular target and could contribute to predict prognosis independently in glioma.
© 2021 Ying Yang et al., published by De Gruyter.

Entities:  

Keywords:  calumenin; epithelial-mesenchymal transition; glioma

Year:  2021        PMID: 33623713      PMCID: PMC7885298          DOI: 10.1515/tnsci-2021-0004

Source DB:  PubMed          Journal:  Transl Neurosci        ISSN: 2081-6936            Impact factor:   1.757


  38 in total

1.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 2.  Calumenin and fibulin-1 on tumor metastasis: Implications for pharmacology.

Authors:  Pengli Zheng; Qiao Wang; Junlin Teng; Jianguo Chen
Journal:  Pharmacol Res       Date:  2015-05-12       Impact factor: 7.658

3.  A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.

Authors:  D Voora; D C Koboldt; C R King; P A Lenzini; C S Eby; R Porche-Sorbet; E Deych; M Crankshaw; P E Milligan; H L McLeod; S R Patel; L H Cavallari; P M Ridker; G R Grice; R D Miller; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-03-03       Impact factor: 6.875

4.  Identification and evaluation of metastasis-related proteins, oxysterol binding protein-like 5 and calumenin, in lung tumors.

Authors:  Kazuya Nagano; Sunao Imai; Xiluli Zhao; Takuya Yamashita; Yasuo Yoshioka; Yasuhiro Abe; Yohei Mukai; Haruhiko Kamada; Shinsaku Nakagawa; Yasuo Tsutsumi; Shin-Ichi Tsunoda
Journal:  Int J Oncol       Date:  2015-05-11       Impact factor: 5.650

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  pROC: an open-source package for R and S+ to analyze and compare ROC curves.

Authors:  Xavier Robin; Natacha Turck; Alexandre Hainard; Natalia Tiberti; Frédérique Lisacek; Jean-Charles Sanchez; Markus Müller
Journal:  BMC Bioinformatics       Date:  2011-03-17       Impact factor: 3.307

7.  Identification of novel molecular targets for endometrial cancer using a drill-down LC-MS/MS approach with iTRAQ.

Authors:  Sébastien N Voisin; Olga Krakovska; Ajay Matta; Leroi V DeSouza; Alexander D Romaschin; Terence J Colgan; K W Michael Siu
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

8.  Protective effect of miR378* on doxorubicin-induced cardiomyocyte injury via calumenin.

Authors:  Yu Wang; Xiaoxue Cui; Yilin Wang; Yao Fu; Xin Guo; Jie Long; Chengxi Wei; Ming Zhao
Journal:  J Cell Physiol       Date:  2018-04-17       Impact factor: 6.384

9.  miR-let-7b and miR-let-7c suppress tumourigenesis of human mucosal melanoma and enhance the sensitivity to chemotherapy.

Authors:  Huan Tang; Meng Ma; Jie Dai; Chuanliang Cui; Lu Si; Xinan Sheng; Zhihong Chi; Longwen Xu; Sifan Yu; Tianxiao Xu; Junya Yan; Huan Yu; Lu Yang; Yan Kong; Jun Guo
Journal:  J Exp Clin Cancer Res       Date:  2019-05-22

10.  Establishment of a CALU, AURKA, and MCM2 gene panel for discrimination of metastasis from primary colon and lung cancers.

Authors:  Parinaz Nasri Nasrabadi; Zahra Nayeri; Ehsan Gharib; Reza Salmanipour; Fatemeh Masoomi; Forouzandeh Mahjoubi; Alireza Zomorodipour
Journal:  PLoS One       Date:  2020-05-29       Impact factor: 3.240

View more
  2 in total

1.  Exploring the Immune Infiltration Landscape and M2 Macrophage-Related Biomarkers of Proliferative Diabetic Retinopathy.

Authors:  Zhishang Meng; Yanzhu Chen; Wenyi Wu; Bin Yan; Yongan Meng; Youling Liang; Xiaoxi Yao; Jing Luo
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-27       Impact factor: 6.055

2.  S100A6, Calumenin and Cytohesin 2 as Biomarkers for Cutaneous Involvement in Systemic Sclerosis Patients: A Case Control Study.

Authors:  Paul Balanescu; Eugenia Balanescu; Cristian Baicus; Anca Balanescu
Journal:  J Pers Med       Date:  2021-05-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.